Ventana Inks CDx Deal with Syndax for Lung Cancer Drug | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ventana Medical Systems and Syndax Pharmaceuticals have signed an agreement for the development of a companion diagnostic for a drug being developed by Syndax to treat non-small cell lung cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.